Merck Maintains No Change In APPROVe Results Despite Correction
This article was originally published in The Pink Sheet Daily
Executive Summary
The company corrected the description of statistical methods used in the Vioxx study.
You may also be interested in...
Vioxx Short-Term Risk Highlighted In NEJM Correction
NEJM analysis shows heart risk associated with rofecoxib may increase prior to 18 months of treatment.
Vioxx Short-Term Risk Highlighted In NEJM Correction
NEJM analysis shows heart risk associated with rofecoxib may increase prior to 18 months of treatment.
Merck’s Vioxx Extension Study Does Not Show An Increased Risk Of Heart Attack
Preliminary analysis shows that there was not a statistically significant difference in the risk of confirmed thrombotic cardiovascular events for patients previously on Vioxx compared to placebo.